About Windtree Therapeutics
Windtree Therapeutics is a company based in Philadelphia (United States) founded in 1992. Windtree Therapeutics has raised $44.98 thousand across 16 funding rounds from investors including HHS and Lee’s PHARM. The company has 14 employees as of December 31, 2024. Windtree Therapeutics has completed 2 acquisitions, including CommLoan and Titan Environmental Solutions. Windtree Therapeutics offers products and services including Istaroxime, SERCA2a Activators, a PKC i Inhibitors, and Rostafuroxin. Windtree Therapeutics operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
- Headquarter Philadelphia, United States
- Employees 14 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Windtree Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$1.79 M (USD)91.19as on Dec 31, 2024
-
EBITDA
-$24.93 M (USD)-42.84as on Dec 31, 2024
-
Total Equity Funding
$44.98 K (USD)
in 16 rounds
-
Latest Funding Round
$253.33 K (USD), Post-IPO
Jul 04, 2025
-
Investors
HHS
& 1 more
-
Employee Count
14
as on Dec 31, 2024
-
Investments & Acquisitions
CommLoan
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Windtree Therapeutics
Windtree Therapeutics is a publicly listed company on the OTC with ticker symbol WINT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Windtree Therapeutics
Windtree Therapeutics offers a comprehensive portfolio of products and services, including Istaroxime, SERCA2a Activators, a PKC i Inhibitors, and Rostafuroxin.
Therapy that improves heart function through dual mechanisms.
Compounds activating SERCA2a for chronic heart failure management.
Inhibitors targeting enzymes for potential heart disease treatments.
Drug for addressing specific cardiovascular conditions.
People of Windtree Therapeutics
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Windtree Therapeutics
Windtree Therapeutics has successfully raised a total of $44.98K across 16 strategic funding rounds. The most recent funding activity was a Post-IPO round of $253.33 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Windtree Therapeutics
Windtree Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Lee’s PHARM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Innovative biopharmaceutical products are developed to address unmet medical needs.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Windtree Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Windtree Therapeutics
Windtree Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CommLoan and Titan Environmental Solutions.
Investment portfolio details for Windtree Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Waste reduction, collection, recycling, and technology solutions are provided.
|
Locked | Locked | 2016 | Locked | |
|
Business loans are matched online between borrowers and lenders.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for Windtree Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Windtree Therapeutics
Detailed financials for Windtree Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Windtree Therapeutics Comparisons
Peer comparison for Windtree Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Windtree Therapeutics
Windtree Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis
|
|
| Locked | Locked | Locked |
Therapies for respiratory-related cardiopulmonary disorders are developed.
|
|
| Locked | Locked | Locked |
Respiratory disease drugs for asthma and COPD are developed.
|
Detailed competitors of Windtree Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Windtree Therapeutics
Complete news archive for Windtree Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Windtree Therapeutics
Windtree Therapeutics was founded in 1992 and raised its 1st funding round 18 years after it was founded.
Windtree Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Windtree Therapeutics is a funded company, having raised a total of $44.98K across 16 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Windtree Therapeutics is 14.
Windtree Therapeutics was founded in 1992 as a biotechnology firm based in Philadelphia, United States. Focus is placed on KL4 surfactant technologies that mimic human pulmonary surfactant for treating respiratory conditions. Drug-delivery methods are explored for aerosolized administration. The pipeline features aerosurf in phase 2 trials for respiratory distress syndrome, alongside preclinical work on aerosolized KL4 for viral, radiation, and chemical lung injuries.
Windtree Therapeutics's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Windtree Therapeutics offers Istaroxime, SERCA2a Activators, a PKC i Inhibitors, and Rostafuroxin.
Yes, Windtree Therapeutics is publicly traded on OTC under the ticker symbol WINT.
Windtree Therapeutics has made 2 acquisitions, including CommLoan, and Titan Environmental Solutions.
Windtree Therapeutics has 2 investors. Key investors include HHS, and Lee’s PHARM.
The ticker symbol of Windtree Therapeutics is WINT on OTC.